- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07940387
IV Lidocaine in Ortho Trauma Patients
The Efficacy of Perioperative Intravenous Lidocaine as an Opioid Sparing Adjunct for Patients Undergoing Lower Extremity Orthopedic Trauma Surgery
In this research study, we will be evaluating whether an anesthesia provider using the method of intravenous lidocaine infusion during the perioperative and immediate postoperative period can provide equal short-term pain control and decrease postoperative opioid consumption compared to traditional opioid utilization. We will also evaluate the effects of intravenous lidocaine on inflammatory mediators such as interleukins and cytokines through timed lab draws. The study hypothesis is that intravenous lidocaine will provide similar pain relief and decrease the amount of post operative opioids used, as well as decrease the amount of inflammatory mediators present compared to conventional post-operative treatment utilizing solely opioids.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Reclutamento
- Detroit Receiving Hospital
-
Contatto:
- Jessica Phillips, PhD, CRNA
- Numero di telefono: 313-577-9239
- Email: fy9015@wayne.edu
-
Contatto:
- Mary Golinski, PhD, CRNA
- Numero di telefono: 248 364 8776
- Email: golinski@oakland.edu
-
Investigatore principale:
- Jessica Phillips, PhD, CRNA
-
Investigatore principale:
- Mary Golinski, PhD, CRNA
-
Investigatore principale:
- Wael Saasouh, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- ASA physical status I-III, males and females >18 years of age and < 85 years of age, scheduled for repair of lower extremity (orthopedic) fracture/s of a single extremity. The type of injury will be documented and categorized- as applicable- in demographic data. The type of fracture will be extracted from the electronic surgical/operative report i.e. preoperative and postoperative diagnosis.
Exclusion Criteria:
- Contraindication to lidocaine including allergy, substantial hepatic impairment (alanine aminotransferase greater than 120 IU/L or aspartate aminotransferase > 80 IU/L), substantial renal impairment (serum creatinine >2 mg/dL), current history of narcotic abuse, cognitive impairment (any patients who are alert and oriented x2 or less; for example, 0-2), cardiac ejection fraction less than 20% by documented cardiac consultation and evaluation, history of seizure disorders, and patients with documented sensory impairments such as neuropathies, fibromyalgia, and diabetes mellitus with concomitant neuropathies (because these sensory impairments may confound postoperative measurements of pain). Cardiac Ejection Fraction less than 20% further explained: Patients who are admitted to the hospital and scheduled for surgery that are deemed high cardiac risk (by history and physical and/or per patient) routinely have echocardiograms per standard of care, and if necessary further cardiac consultations and 'work ups' are performed at Detroit Receiving Hospital. With the thorough history and physical that is required, the results will be available prior to surgery and anesthesia. If a patient has demonstrated 'no cardiac risk factors' after a complete history and physical examination, they will be assumed to have a normal ejection fraction. Pregnant women will also be excluded as there have been no controlled studies in humans investigating the potential effects of intravenous lidocaine during pregnancy. All patients undergo a serum or urine HCG test prior to surgery, and these will be evaluated by the researchers.
Patients under the age of 18 will be excluded due to recent studies finding adverse reactions, although mild, appear to be common in children. Oxygen saturation of <95% on room air will be excluded per the lidocaine package insert. Weight of 150 kg (330 lbs) will be excluded per the lidocaine package insert.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Control Group - Saline Infusion
Saline bolus and infusion |
Saline infusion |
|
Sperimentale: Intervention - IV Lidocaine Group
Lidocaine bolus and infusion |
A Lidocaine (LID) bolus 2mg/kg followed by an infusion rate of 2 mg/kg/hr. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Morphine equivalents
Lasso di tempo: from enrollment to 14 days postoperative
|
Amount of opioids in morphine milligram equivalents (MME) used in 2 weeks/14 days postoperative period |
from enrollment to 14 days postoperative
|
|
Interleukin 6 (IL-6)
Lasso di tempo: 1, 6, 24 and 48 hours postoperative
|
Interleukin 6 (IL-6) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL |
1, 6, 24 and 48 hours postoperative
|
|
Interleukin 8 (IL-8)
Lasso di tempo: 1, 6, 24 and 48 hours postoperative
|
Interleukin 8 (IL-8) present in serum plasma at 1, 6, 24 and 48 hours postoperative in pg/mL |
1, 6, 24 and 48 hours postoperative
|
|
Complement C3a
Lasso di tempo: 1, 6, 24 and 48 hours postoperative
|
Complement C3a present in serum plasma at 1, 6, 24 and 48 hours postoperative in ng/mL |
1, 6, 24 and 48 hours postoperative
|
|
Visual Analogue Pain Score
Lasso di tempo: Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.
|
Visual Analogue Pain Score with 0 = no pain and 10 = worst pain ever. |
Pain will be evaluated at 30-min intervals in post anesthesia care unit (PACU) and every 4 hr. thereafter up to 48 hour postoperative.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Quantitative Sensory Testing
Lasso di tempo: Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)
|
Mechanical and thermal pain thresholds will be measured adjacent to the incision site to measure hyperalgesia |
Postoperative day 1, day 3, and at the follow up first appointment with surgeon (approximately two weeks postoperatively)
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRB 24-11-7305
- 2025-G-5 (Altro numero di sovvenzione/finanziamento: AANA Foundation)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Any information containing patient information or protected health information (PHI) such as master list documents containing patient names and medical record numbers will be stored securely in a locked office inside a locked filing cabinet at the DMC site. All other data will use a subject number assigned and remove all 18 types of PHI information De-identified and be hard copies (paper records) will also be stored securely in a locked office inside a locked filing cabinet. DMC collected data will be saved on the DMC secure server in the Citrix platform. Study data will only be accessible to investigators involved in the study. Statistical analysis will be performed on de-identified encrypted digital data.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .